Korea approves first anti-COVID-19 monoclonal antibody treatment

Korea approves first anti-COVID-19 monoclonal antibody treatment
08 February 2021 | News
CT-P59 is approved for the treatment of patients aged 60 years and over, or with at least one underlying medical condition, with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID- 19
Photo Credit: Freepik
Celltrion Group has announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted conditional marketing authorization (MA) for the emergency use of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate. Conditional Marketing Authorization allows emergency use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, elevated blood pressure) mild symptoms of COVID-19, and in adult patients with moderate symptoms of COVID-19.

Related Keywords

South Africa ,United Kingdom ,South Korea ,South African ,British , ,Celltrion Group ,Ministry Of Food ,Drug Safety ,Conditional Marketing Authorization ,Country Code Phone Number ,Celltrion ,Anti Covid 19 Monoclonal Antibody Treatment ,039 Regdanvimab ,ஒன்றுபட்டது கிஂக்டம் ,தெற்கு கொரியா ,பிரிட்டிஷ் ,அமைச்சகம் ஆஃப் உணவு ,மருந்து பாதுகாப்பு ,நிபந்தனை சந்தைப்படுத்தல் அங்கீகாரம் ,நாடு குறியீடு தொலைபேசி எண் ,